期刊文献+

阿法替尼和吉非替尼分别联合培美曲塞对人肺腺癌细胞作用的研究 被引量:9

The inhibitory effects of the combination of pemetrexed and BIBW2992 or gefitinib respectively on human lung adenocarcinoma cell line
暂未订购
导出
摘要 目的探讨阿法替尼(BIBW2992)和吉非替尼分别与培美曲塞联合对肺腺癌细胞PC-9(突变敏感型)、H1975(T790M耐药型)的增殖和凋亡的影响并阐述其可能机制。方法 MTT法检测细胞增殖,流式细胞仪检测细胞凋亡及细胞周期变化,Western blot法检测不同浓度BIBW2992和吉非替尼对细胞胸苷酸合成酶(TS)表达水平的影响。结果 BIBW2992、吉非替尼以及培美曲塞单独作用后,PC-9和H1975细胞均明显凋亡,同时细胞增殖受到不同程度抑制。BIBW2992与培美曲塞联合在PC-9、H1975细胞中对细胞的增殖抑制及诱导凋亡作用较单药组均有明显提高(P<0.05),而吉非替尼与培美曲塞联合仅在PC-9细胞中提高单药对细胞的增殖抑制及诱导凋亡作用(P<0.05)。BIBW2992在PC-9、H1975细胞中均显著降低TS表达,而吉非替尼在H1975细胞中无显著抑制作用。结论 BIBW2992可以克服T790M突变耐药,并且与培美曲塞联合对PC-9、H1975细胞呈协同增效作用;吉非替尼与培美曲塞联合仅对PC-9细胞具有协同增效作用,可能主要与下调TS表达作用有关。 Objective To investigate the potential anti-proliferative and pro-apoptotic effects of the combination of pemetrexed and afatinib(BIBW2992) or gefitinib respectively on gefitinib-sensitive cells (PC-9) and gefitinib-re-sistant cells with the T790M mutation of EGFR(H1975) and explore its possible anti-cancer mechanism. Methods MTT assay was performed to reveal the inhibitory effect on cell proliferation. Flow cytometry using annexin V-FITC/PI staining was employed to measure the cell apoptosis and cell cycle. Western blot was performed to detect the protein expressions of thymidylate synthase ( TS) after treated with different dose of BIBW2992 and gefitinib re-spectively . Results The PC-9 and H1975 cells were inhibited to different degrees after treatment with BIBW2992 , gefitinib and pemetrexed alone and had apparent apoptotic features. The combined treatment with BIBW2992 and pemetrexed resulted in a synergistic effect in inducing apoptosis and inhibiting cell proliferation compared with BIBW2992 and pemetrexed alone both on the PC-9 and H1975 cells(P〈0. 05). The combined treatment with ge-fitinib and pemetrexed resulted in a synergistic effect only on the PC-9 cells(P〈0. 05), whereas had no such syn-ergistic effect on the H1975 cells. The BIBW2992 decreased the expressions of TS apparently both on the PC-9 cells and H1975 cells, whereas gefitinib had no such effect on the H1975 cells. Conclusion The BIBW2992 can overcome the drug resistance of cells with the T790M mutation of EGFR. The combination of BIBW2992 and peme-trexed has an enhanced antitumor effect on both PC-9 cells and H1975 cells, whereas the combination of gefitinib and pemetrexed has an enhanced antitumor effect only on PC-9 cells, with the possible mechanism of ability to sup-press the expression of TS.
出处 《安徽医科大学学报》 CAS 北大核心 2014年第6期772-776,共5页 Acta Universitatis Medicinalis Anhui
基金 南京军区医学科技创新课题项目(编号:ZD19)
关键词 BIBW2992 吉非替尼 肺癌 细胞周期 细胞凋亡 BIBW2992 gefitinib adenocarcinoma cell cycle cell apoptosis
  • 相关文献

参考文献14

  • 1Miller V A,Hirsh V,Cadranel J,et al.Afatinib versus plac,ebo for patient with advanced,metastatic non-small-cell lung cancer after failure of erlotinib,gefitinib,or both,and one or two lines of chemotherapy(LUX-Lung 1):a phase 2b/3 randomised trial[J].Lancet Oneol,2012,13(5):528-38.
  • 2Katakami N,Atagi S,Goto K,et al.Lux-Lung 4:a phase Ⅱ tri-al of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib,gefitinib,or both[J].J ClinOncol,2013,31(27):3335-41.
  • 3Onitsuka T,Uramoto H,Nose N,et al.Acquired resistance to ge-fitinib:the contribution of mechanisms other than the T790M,MET,and HGF status [J].Lung Cancer,2010,68(2):198-203.
  • 4Yang J C,Shih J Y,Su W C,et al.Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor muta-tions(LUX-Lung 2):a phase 2 trial [J].Lancet Oncol,2012,13(5):539-48.
  • 5Yang J C,Schuler M H,Yamamoto N,et al.LUX-Lung 3:A ran-domized,open-label,phase Ⅲ study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced ade-nocarcinoma of the lung harboring EGFR-activating mutations [J].J Clin Oncol,2012,30(Suppl):a LBA7500.
  • 6Takezawa K,Okamoto I,Tanizaki J,et al.Enhanced anticancer effect of the combination of BIBW2992 and thymidylate synthase-targeted agents in non-small cell lung cancer with the T790M mu-tation of epidermal growth factor receptor[J].Mol Cancer Ther,2010,9(6):1647-56.
  • 7Eskens F A,Mom C H,Planting A S,et al.A phase I dose esca-lation study of BIBW 2992,an irreversible dual inhibitor of epider-mal growth factor receptor 1(EGFR)and 2(HER2)tyrosine ki-nase in a 2-week on,2-week off schedule in patients with ad-vanced solid tumours[J].Sr J Cancer,2008,98(1):80-5.
  • 8Kobayashi S,Ji H,Yuza Y,et al.An ahemative inhibitor over-comes resistance caused by a mutation of the epidermal growth fac-tor receptor[J].Cancer Res,2005,65(16):7096-101.
  • 9Engelman J A,Zejnullahu K,Gale C M,et al.PF00299804,an irreversible pan-ERBB inhibitor,is effective in lung cancer models with EGFR and ERBB2 mutations that arc resistant to gefitinib [J].Cancer Res,2007,67(24):11924-32.
  • 10Von Pawel J,Papai-Szekely Z,Vinolas N,et al.A randomized phase Ⅱ study of pemetrexed versus pemetrexed plus erlotinib in second-line treatment for locally advanced or metastatic,nonsqua-mous NSCLC [J].J Clin Oncol,2011,29(Suppl):a7526.

同被引文献78

  • 1徐磊,赵松,党丽峰,齐宇,杨洋,刘东雷,吴恺,王啸林,鲍培龙.自噬在厄洛替尼诱导的肺腺癌细胞A549凋亡中的作用[J].中国老年学杂志,2014,34(8):2197-2198. 被引量:1
  • 2曹喆,庄亮,陈元.吉非替尼对肺癌细胞株A549和H1975放射敏感度的影响及其机制[J].肿瘤防治研究,2014,41(4):324-330. 被引量:5
  • 3Matikas A, Mistriotis D, Georgoulias V, et al. Current and futureapproaches in the management of non-smali-cell lung cancer pa-tients with resistance to EGFR TKIs [ J ]. Clin Lung Cancer,2015, 16(4):252-261.
  • 4Dhillon S. Gefitinib : a review of its use in adults with advancednon-small cell lung cancer[ J]. Target Oncol,2015,10( 1) : 153-170.
  • 5Thress KS, Paweletz CP, Felip E, et al. Acquired EGFR C797Smutation mediates resistance to AZD9291 in non-small cell lungcancer harboring EGFR T790M[J]. Nat Med, 2015, 21(6):560-562.
  • 6So KS,Kim CH, Rho JK, et al. Autophagosomenmediated EGFRdown-regulation induced by the CK2 inhibitor enhances the effi-cacy of EGFR-TKI on EGFR-mutant lung cancer cells with resist-ance by T790M[/OL]. PLoS One, 2014, 9( 12) [2015-04-16] .http: //www.ncbi.nlm.nih.gov/ pmc/ articles/PMC4259313 .
  • 7Kobayashi S, Ji H, Yuza Y, et al. An alternative inhibitor over-comes resistance caused by a mutation of the epidermal growthfactor receptor[ J]. Cancer Res, 2005,65(16):7096-7101.
  • 8Kancha RK, von Bubnoff N, Bartosch N, et al. Differential sen-sitivity of ERBB2 kinase domain mutations towards lapatinib [ J/OL]. PLoS One, 2011, 6(10) [ 2015-04-22 ]. http://www.ncbi.nlm.nih.gov/pmc/ articles/PMC3203921.
  • 9D,Angelo SP, Pietanza MC, Johnson ML, et al. Incidence of EG-FR exon 19 deletions and L858R in tumor specimens from menand cigarette smokers with lung adenocarcinomas [ J ]. J Clin On-col, 2011, 29(15):2066-2070.
  • 10Nakagawa T, Takeuchi S, Yamada T, et al. Combined therapywith mutant-selective EGFR inhibitor and Met kinase inhibitor forovercoming erlotinib resistance in EGFR-mutant lung cancer[ J].Mol Cancer Ther, 2012,11(10):2149-2157.

引证文献9

二级引证文献41

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部